ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
113.09
-0.45 (-0.40%)
At close: 4:00PM EST

112.96 -0.13 (-0.12%)
After hours: 5:08PM EST

Stock chart is not supported by your current browser
Previous Close113.54
Open114.01
Bid111.50 x 200
Ask115.00 x 100
Day's Range111.80 - 114.55
52 Week Range96.18 - 149.34
Volume1,624,438
Avg. Volume2,084,187
Market Cap25.265B
Beta1.07
PE Ratio (TTM)50.53
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alexion Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALXN-US. Comparing the performance and risk of Alexion Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Market Realist3 days ago

    Analyst Recommendations for Alexion in December 2017

    Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”

  • Alexion (ALXN) in Focus: Stock Moves 7.2% Higher
    Zacks3 days ago

    Alexion (ALXN) in Focus: Stock Moves 7.2% Higher

    Alexion (ALXN) shares rose more than 7% in the last trading session, amid huge volumes.

  • Zacks3 days ago

    4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

    Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

  • Market Realist3 days ago

    Alexion Pharmaceuticals’ Strensiq and Kanuma after 3Q17

    In 3Q17, Alexion Pharmaceuticals' (ALXN) Strensiq generated revenues of $87 million compared to $61 million in 3Q16, a 43% growth YoY and a 5% growth QoQ.

  • Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018
    MarketWatch4 days ago

    Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018

    Last year’s list is a mixed bag, which is why you ought to invest for the long run. By Phil van Doorn.

  • Reuters6 days ago

    Elliott Management seeks changes at Alexion - NYT

    If Alexion failed to offer more aggressive financial performance guidance or consider strategic alternatives such as a sale, Elliott could start a proxy fight to claim board seats, the paper reported, citing people who were not authorized to speak publicly. In a recent meeting between Alexion and Elliott, the hedge fund sought to have more biotech experts as directors and suggested four potential candidates, the newspaper said. "Alexion believes in active and constructive dialogue with all of our shareholders, and we value their perspective," a company spokeswoman said in an emailed statement on Friday.

  • Reuters6 days ago

    Elliott Management seeks changes at Alexion - NYT

    U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday. If Alexion failed to offer more aggressive financial performance guidance or consider strategic alternatives such as a sale, Elliott could start a proxy fight to claim board seats, the paper reported, citing people who were not authorized to speak publicly. In a recent meeting between Alexion and Elliott, the hedge fund sought to have more biotech experts as directors and suggested four potential candidates, the newspaper said.

  • Market Realist6 days ago

    A Look at Alexion Pharmaceuticals’ Soliris after 3Q17

    In 3Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of $756 million, a 4% growth YoY (year-over-year) and a 7% fall QoQ (quarter-over-quarter).

  • Barrons.com6 days ago

    The Hot Stock: Alexion Pharmaceuticals Jumps 7.2%

    Shares of  Alexion Pharmaceuticals (ALXN) shot to the top of the S&P 500 today, on reports that an activist investor is pushing for more shareholder value creation. Alexion rose $7.68, or 7.2% to $114.46, while the S&P 500 climbed 14.52 points, or 0.6%, to 2651.50.  The stock jumped after reports that the hedge fund Elliott Management, is urging the company to make more changes.

  • Why This Biotech Could See 30% Upside In The Second Quarter
    Investor's Business Daily6 days ago

    Why This Biotech Could See 30% Upside In The Second Quarter

    Alexion could see as much as 30% upside if its rare blood disease drug outperforms its approved drug Soliris in a pair of Phase 3 trials.

  • Market Realist6 days ago

    How Is Alexion Pharmaceuticals Positioned after 3Q17?

    In 3Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $859 million, which represented an 8% growth YoY (year-over-year) and a 6% fall QoQ (quarter-over-quarter).

  • 5 Cheap Biotech Stocks to Snag on the Bounce
    InvestorPlace6 days ago

    5 Cheap Biotech Stocks to Snag on the Bounce

    One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP’s corporate tax cut plans.

  • Barrons.com6 days ago

    Elliott Management Flexes Muscle at Alexion

    Shares of  Alexion Pharmaceuticals (ALXN) are jumping on Friday, following reports that activist investor Elliott Management is pushing for changes at the company.  Alexion has had a tough year, falling some 7% since the start of 2017, a year that has seen the iShares Nasdaq Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI)  climb double digits, so it's no surprise that investors are annoyed. Elliott Management, which has built a stake in the company, is urging Alexion to do more to boost its shares, according to sources close to the situation that could only speak to the New York Times anonymously. Of course Elliott Management is no stranger to picking fights with companies, as its previously sparred with Samsung Electronics ( 009530KS )  and waged a proxy battle at Arconic (ARNC).

  • American City Business Journals6 days ago

    Boston-bound Alexion sees shares jump amid reported activist pressure

    Activist hedge fund Elliott Management has targeted two high-profile local companies in recent years, pushing for changes at EMC before it was acquired by Dell, and, more recently, instigating cost-cutting measures at Watertown-based health IT firm athenahealth. According to a New York Times report late Thursday, Elliott has now set its sights on Alexion Pharmaceuticals (ALXN), a rare disease drugmaker that is planning to move its headquarters from Connecticut to Boston next year. The newspaper, citing two unnamed sources with knowledge of Elliott’s plans, said that the hedge fund has taken a stake in Alexion and is urging the company “to do more to lift its stock price.” The report raised the possibility that Elliott could launch a proxy battle to gain seats on Alexion’s board, or even push for a sale, if the company doesn’t meet its demands.

  • TheStreet.com6 days ago

    Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

    A report says activist hedge fund Elliott Management wants plans to boost Alexion's share price or it will start a proxy fight for seats on the board.

  • 24/7 Wall St.6 days ago

    Will Alexion Pharmaceuticals Fight This Activist?

    Alexion Pharmaceuticals shares saw a handy gain early on Friday after the New York Times reported that there might be some increasing activist movement in the stock.

  • The Wall Street Journal6 days ago

    Stocks to Watch: Amazon, Caterpillar, Alexion, 3M, United Continental, American Outdoor

    Among the companies with shares expected to trade actively in Friday's session are Amazon.com, Caterpillar, Alexion Pharmaceuticals, 3M, United Continental and American Outdoor.

  • Stocks making the biggest moves premarket: GM, NKE, ALXN, TRVG & more
    CNBC6 days ago

    Stocks making the biggest moves premarket: GM, NKE, ALXN, TRVG & more

    These are the stocks posting the largest moves before the bell.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Reuters7 days ago

    PRESS DIGEST-New York Times business news - Dec 8

    The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Ford Motor Co is shifting production of a future ...

  • Barrons.com7 days ago

    Barron's After Hours: Forescout Jumps, Alexion Gains, Smith & Wesson Parent Slumps

    After a four day losing streak U.S. stocks closed higher on Thursday with the S&P 500 and the Dow Jones Industrial Average both gaining 0.3%, while the the Nasdaq Composite gained 0.5%. Asia-Pacific markets ...

  • TheStreet.com7 days ago

    Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

    The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

  • Why Alexion Pharmacteuicals Sank 8.9% in November
    Motley Fool9 days ago

    Why Alexion Pharmacteuicals Sank 8.9% in November

    A handful of positive updates still wasn't enough to reverse the negative sentiment.

  • Why Ra Pharmaceuticals, Inc. Got Hammered Today
    Motley Fool10 days ago

    Why Ra Pharmaceuticals, Inc. Got Hammered Today

    "Positive" phase 2 data for RA101495 SC wasn't positive enough.